Join the waitlist and get 1 year of free service for early adopters of our apps
Clicking "Submit" implies agreement to our Privacy Policy and Terms of Service
“Health is the right, not a priviledge”
— Omid Hamid, M.D.
Director, Clinical Research and Immunotherapy at The Angeles Clinic and Research Insititute
AI-Powered Decision Support for Oncology Imaging
We are prototyping radiomics technology to analyze multiple data points across various timeframes, aiming to provide valuable insights on tumor density, kinetics, and the likelihood of malignancy.
Currently, we are developing and training models for lung and brain cancers.
Advantages of Medaici
Today
Personalization
AML models can help perosnalize cancer care by taking into account a patient’s individual needs and preferences. This can improve patient satisfaction and engagement with their treatment plan.
Efficiency and Cost Savings
ML-powered tools can automate tasks such as data analysis and triage, allowing clinicians to focus on providing care. This can improve efficiency and reduce costs associated with manual data analysis.
Tomorrow
Precision Medicine
ML algorithms can analyze large datasets of patient information to help determine the most effective treatment plan based on their unique genetic and clinical characteristics. This can improve patient outcomes and reduce the risk of ineffective treatments.
Predictive Analytics
ML algorithms can be used to predict which patients are at high risk for developing cancer or experiencing treatment complications. This can help clinicians intervene earlier and provide more targeted care.
Research
ML models can analyze large datasets of cancer research to identify trends and potential treatments. This can aid in collaboration and refinement of assessments, ultimately accelerating the pace of cancer research and drug development.
Xenograft models
can provide invaluable data that extends beyond the lifespan of the original patient and is available in perpetuity. By using Xenograft models, researchers can study the behavior and characteristics of tumors over extended periods of time, which can help to inform the development of new cancer treatments and therapies.
Meet the Team
-
Dr. Omid Hamid M.D.
CEO
Director of the Melanoma Center, Phase | Immuno-Oncology Program and Clinical Research and Immunotherapy at The Angeles Clinic and Research Institute (part of Cedars Sinai). 24 years in oncology.
USC -
Dr. Jinha Park, M.D. PHD
Radiology Expert
Former Chief of Body Imaging at University of Iowa and Chief of Oncology at vRad. Private Practice Radiologist.
UC Berkeley
USC
UCLA
Stanford -
Dr. Melinda Chu, M.D. MBA
Clinical Research
Technology and healthcare professional. Al in healthcare enthusiast and promoter.
Princeton -
Julius Bogdan
Product Strategy
VP and GM @ HIMSS: Healthcare Information and Management Systems. 16 years in Microsoft. Data analytics and ML expert. Stanford
-
Vitaly N. Dubinin
Operations
Serial entrepreneur. 15 years in software management and business development.
ILF Frankfurt
Join the waitlist and get 1 year of free service for early adopters of our apps
By clicking submit above, you consent to allow Medaici to store and process the personal information submitted above to provide you the content requested.